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Locally released oxytocin (OT) activates OT receptors (2.1:OXY:1:OT:) in 
neighboring neurons in the hypothalamus and their terminals in the posterior 
pituitary, resulting in further OT release, best known in autoregulation occurring 
during labor or milk ejection in reproductive females. OT also plays a critical role 
in social behavior of non-reproductive females and even in males in mammals from 
rodents to humans. Social behavior is disrupted when elevation of free intracellular 
Ca2+ concentration ([Ca2+]i) and OT secretion are reduced in male and female 
CD38 knockout mice. Therefore, it is interesting to investigate whether 
ADP-ribosyl cyclase-dependent signaling is involved in OT-induced OT release for 
social recognition in males, independent from female reproduction, and to 
determine its molecular mechanism. Here, we report that ADP-ribosyl cyclase 
activity was increased by OT in crude membrane preparations of the 
hypothalamus and posterior pituitary in male mice, and that OT elicited an 
increase in [Ca2+]i in the isolated terminals over a period of 5 min. The increases in 
cyclase and [Ca2+]i were partially inhibited by nonspecific protein kinase inhibitors 
and a protein kinase C specific inhibitor, calphostin C. Subsequently, OT-induced 
OT release was also inhibited by calphostin C to levels inhibited by vasotocin, an 
OT receptor antagonist, and 8-bromo-cADP-ribose. These results demonstrate that 
OT receptors are functionally coupled to membrane-bound ADP-ribosyl cyclase 
and/or CD38 and suggest that cADPR-mediated intracellular calcium signaling is 
involved in autoregulation of OT release, which is sensitive to protein kinase C, in 
the hypothalamus and neurohypophysis in male mice.
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1. Introduction 
Oxytocin (OT), a peptide of the vasopressin and OT family, plays a critical role in 
social recognition and behavior in mammals from rodents to humans (Donaldson and 
Young, 2008; Neumann, 2008). This short polypeptide hormone is secreted 
dendritically from neurons in the paraventricular nucleus (PVN) and supraoptic nucleus 
(SON) of the hypothalamus and spread to other areas of the brain (McGregor et al., 
2008; Skuse and Gallgher, 2009). Locally released OT in the brain causes excitation of 
OT neurons by activating OT receptors, a class A family (2.1:OXY:1:OT: in IUPHA 
data base; http://www.iuphar-db.org/GPCR/ReceptorListForward?class=class%20A), 
expressed on both neurons of the PVN and SON and nerve endings in the posterior 
pituitary (Adan et al., 1995; Freund-Mercier et al., 1994; Young et al., 1997). This 
excitation leads to facilitative OT release, known as autoregulation (Moos et al., 1984; 
Neumann et al., 1996). The autoregulation of OT-induced OT release occurs during 
uterine contraction in labor and milk ejection in lactation (Richard et al., 1991). 
However, it is not yet clear whether this autoregulation functions during non-productive 
daily life in males and in non-reproductive females.  
OT receptors are seven-transmembrane domain proteins that couple with Gq/11 or G i 
and stimulate the production of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol 
(DAG) through the activation of phospholipase C (PLC) (Gimpl and Fahrenholz, 2001), 
resulting in activation of Ca2+ signals and protein kinase C (PKC). This PLC- and 
IP3-dependent Ca2+ signaling may function in autoregulation (Lambert et al., 1994). 
On the other hand, another Ca2+ signal pathway of cyclic ADP-ribose (cADPR) has 
recently been demonstrated in many tissues, including the nervous system (Lee, 2001; 
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Higashida et al., 2007). Intracellular cADPR concentrations are known to be regulated 
in many different ways: in one such mechanism, ADP-ribosyl cyclase or CD38 seems 
to be coupled directly with neurotransmitter or hormone receptors such as muscarinic 
acetylcholine or metabotropic glutamate receptors via different G proteins on the 
membrane surface (Higashida et al., 1997, 1999, 2007); or phosphorylation 
downstream of the G-protein-coupled receptor signaling pathway (Boittin et al., 2003; 
Sternfeld et al., 2003). Specifically, the activation of ADP-ribosyl cyclase or CD38 by 
cyclic GMP- or cyclic AMP-dependent protein kinases has been reported in Aplysia 
californica (Graeff et al., 1998), LAK cells (Rah et al., 2005) and artery smooth 
muscle cells (Boittin et al., 2003). However, there have been no previous reports 
regarding the mechanisms by which ADP-ribosyl cyclase and CD38 are activated after 
OT receptor stimulation in the hypothalamus, leading to secretion of OT. Here we 
address the above question of whether ADP-ribosyl cyclase/CD38-dependent cADPR 
and [Ca2+]i signaling are involved in the autoregulatory positive feedback of OT 
release in the hypothalamus and posterior pituitary in adult male mice. We 
demonstrated that the activity of ADP-ribosyl cyclase was increased in response to OT, 
resulting in production of cADPR, increases in [Ca2+]i, and facilitation of OT release. 
The OT-induced reactions in the signal cascade were sensitive to PKC inhibitors, and 
the later two reactions after formation of cADPR were inhibited by a cADPR blocker.  
 
 




ICR mice (10 to 12 weeks old, 30-35g body weight) were kept in the animal center 
under standard conditions (24°C; 12-h light/dark cycle, lights on at 8:00 a.m.) with food 
and water ad libitum. For preparing tissues, mice were first anesthetized with diethyl 
ether and mouse heads were cut off by a scissor, in accordance with the guidelines for 
the care and use of laboratory animals of Kanazawa University. 
 
2.2. Materials  
Most drugs were purchased from Sigma (St. Louis, MO, USA). Xestospongin C was 
obtained from Wako (Osaka, Japan). 
 
2.3. ADP-ribosyl cyclase activity 
ADP-ribosyl cyclase activity in the hypothalamus and pituitary were determined 
fluorometrically using nicotinamide guanine dinucleotide (NGD+) as a substrate, with a 
slight modification (Higashida et al., 1997 and 1999) of the method described 
previously (Graeff et al., 1994). The tissues were homogenized in 10 mM Tris-HCl 
buffer, pH 7.4. The fresh homogenates were mixed with reaction solution containing 60 
µM NGD+, 50 mM Tris-HCL, pH 7.0, 100 mM KCL, 10 µM CaCl2 at 37°C with 
constant stirring. The samples were then excited at 300 nm, and fluorescence emission 
was monitored continuously at 410 nm for 10 min in a Shimadzu RF-5300PC 
spectrofluorometer (Kyoto, Japan). Protein content was determined using a Bio-Rad 
protein assay kit and bovine serum albumin as a standard. The specific ADP-ribosyl 
cyclase activity was calculated using cyclic guanosine diphosphate ribose (cGDPR) 
standards, and the results are presented as nM cGDPR per mg protein per minute. 
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2.4. Measurement of tissue cADPR concentrations 
The cADPR content was measured by using a cyclic enzymatic assay as described 
previously (Graeff and Lee, 2002). The hypothalamus was treated with 0.5 ml of 0.6 M 
perchloric acid under sonication. After centrifugation at 20,000 x g for 10 min, 
perchloric acid was removed by mixing the aqueous sample with a solution containing 3 
volumes of 1,1,2-trichlorotrifluoroethane to 1 volume of tri-n-octylamine. The contents 
of this preparation were then measured. 
 
2.5. Preparation of isolated neurohypophysial nerve terminals 
Isolated never terminals were prepared from ICR male mice as previously described 
(OuYang et al., 2004; Sasaki et al., 2005). Briefly, the posterior pituitary lobes were 
carefully removed and incubated in normal Locke’s solution containing (in mM): NaCl, 
140; KCl, 5; MgCl2, 1.2; CaCl2, 2.2; glucose, 10; HEPES, 10; BSA, 0.1%, adjusted to 
pH 7.25 with Tris-HCl. The tissues were gently homogenized using a Teflon 
homogenizer in a solution containing (in mM): sucrose, 270; HEPES, 10; EDTA, 0.2, 
adjusted to pH 7.25 with Tris-HCl. The homogenate was first centrifuged for 1 min at 
1,000 x g, then the supernatant was further spun at 2,400 x g for 4 min. After discarding 
the supernatant, the pellet was resuspended in normal Locke’s solution and loaded onto 




2.6. Measurement of [Ca2+]i in nerve endings 
To monitor the changes of intracellular calcium concentrations after various 
treatments, the isolated nerve endings were incubated with a cell-permeable 
acetoxymethylester form  (Fura-2 AM) of 5 µM Oregon Green 488 
1,2-bis(2-aminophenoxy)ethane-N,N,N,N-tetraacetate (BAPTA-1) (OGB-1; Molecular 
Probes, Invitrogen, Tokyo, Japan) diluted in normal Locke’s solution for 1h at 37°C. 
Nerve endings loaded with Oregon Green 488 BAPTA-1 were illuminated at 
wavelength of 485 nm, and the emission was detected at 538 nm using an Argus 50 
(Hamamatsu Photonics, Hamamatsu, Japan). Image of nerve endings were collected 
every 10 s for up to 5 min. The changes in fluorescence intensity of each nerve ending 
were expanded into an X-t plane. Data are performed in change in fluorescence divided 
by resting fluorescence, i.e., ∆F/F0 (Higashida et al, 2007) .  
 
2.7. OT release from nerve endings 
The prepared nerve endings were perfused with normal Locke’s solution at 0.2 
ml/min for 45 min. At the end of perfusion, the perfusate during 5 min was collected 
three times to determine the basic OT release. Then, the perfusate was changed to 
normal Locke’s solution containing 100 pg/mL OT with or without 2 mM extracellular 
calcium or 1 µM vasotocin. For other signaling inhibition experiments, the nerve 
endings were pre-incubated within the Locke’s solution containing 100 nM Calphosin C, 
100 µM 8-bromo-cADPR or 2 µM Xestospongin C for 30 min at 37°C after perfusion. 
At the end of incubation, a solution with 100 nM Calphosin C, 100 µM 
8-bromo-cADPR or 2 µM Xestospongin C was perfused for periods of 5 min each and 
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samples were collected three times to determine basal OT release. Then, the perfusate 
was changed to 100 pg/mL OT Locke’s solution with 100 nM Calphosin C, 100 µM 
8-bromo-cADPR or 2 µM Xestospongin C, respectively. All the samples were stored at 
-80 °C for later immunoassay. Amount of OT released during 5 min from isolated nerve 
endings on the coated glass was determined by replacing incubation Lock solution with 
or without the known concentration of OT (for stimulation). Therefore, we used the 
following formula to calculate the ratio of OT release under various conditions of pre- 
and post-stimulation: OT release ratio = (OT concentration incubated with OT) – (OT 
concentration without OT)/ (pre-stimulation of OT level=100 pM), according to the 
method described previously (Jin et al., 2007b). 
 
2.8. ELISA assay for OT 
The concentration of OT was determined by using an enzyme-linked 
immunosorbent assay (Assay Designs, Ann Arbor, MI) according to the manufacturer’s 
protocol, as described previously (Jin et al., 2007a). The inter- and intra-assay 
coefficients of variations were 10.7% and 12.2%, respectively, and the sensitivity was 
11.7 pg/mL. 
 
2.9. Statistical analyses  
All data are shown as means ± SE (n=4-6). The statistical analyses were performed 
using SigmaPlot 11.0 (Systat Software Inc. San Jose, CA). A p value of less than 0.05 




3. Results  
 
3.1. Effects of OT on activity of membrane-bound form of ADP-ribosyl cyclase and 
cADPR levels 
  
First, we examined whether application of OT stimulates ADP-ribosyl cyclase 
activity in crude membranes prepared from the hypothalamus and posterior pituitary of 
adult male mice. The effects of various concentrations of OT were examined in crude 
membrane preparations by fluorometric measurement of cGDPR production as an assay 
for ADP-ribosyl cyclase enzyme activity. cGDPR production increased upon exposure 
to OT for 5 min (Fig. 1A and B). The maximum increase in ADP-ribosyl cyclase 
activity in response to 10 nM OT was 158 ± 7% (n=5) of the pre-exposure levels in the 
hypothalamus, while it was 278 ± 57% (n=5) at 10 pM OT in the pituitary. No or little 
activation was detected at higher concentrations of OT in the hypothalamus (100 nM) 
and the pituitary (1 nM). Simultaneous application of vasotocin, an OT receptor 
antagonist, significantly inhibited the OT-induced increase of ADP-ribosyl cyclase 
activity. Vasotocin did not inhibit the basal activity, suggesting little or no oxytocin 
present in the reaction buffer together with membranes as an enzyme source. 
In order to test whether ADP-ribosyl cyclase stimulation by OT required receptor 
coupling to endogenous G proteins, we examined the effect of exogenous GTP in 
well-washed membranes. Addition of 10 nM GTP with or without 10 nM OT resulted in 
a significant increase in enzymatic activity by 33 ± 4% or 41 ± 3% (p<0.05, n=4) in the 
hypothalamic preparations, respectively. Application of 10 nM GTP alone resulted in 
only an increase of 10 %, while GTP together with 10 pM OT caused a significant 
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inhibition of 47 ±7% (p<0.01, n=4) in pituitary nerve endings, suggesting a signal 
pathway via Gq/11 or G i (Gimpl and Fahrenholz, 2001).  
Tissue cADPR concentrations ([cADPR]i) were measured by the enzyme recycling 
method. [cADPR]i in the hypothalamus of male mice was 228 ± 53 nmol/mg protein 
(n=4) before stimulation. [cADPR]i increased during incubation with OT for 5 min in a 
dose-dependent manner. The maximal increase to 1050 ± 72 nmol/mg protein (n=4) 
(4.6-fold higher than the control level) was obtained at the same concentration of 10 nM 
OT for the maximum activation of ADP-ribosyl cyclase (Fig. 2). It is interesting to 
measure the cADPR level in the pituitary in response to OT, which will be reported 
elsewhere. 
 
3.2. Inhibition of OT-induced activation of the ADP-ribosyl cyclase    
 
Next, we examined the possibility that ADP-ribosyl cyclase is also activated by 
protein kinases via the OT-signaling pathway. We first used staurosporine (PKI-STSP), 
one of the most potent and widely used cell permeable inhibitors of protein kinases, to 
measure ADP-ribosyl cyclase activity after OT stimulation for 5 min in the 
hypothalamus and pituitary. A significant inhibition was obtained with 5 nM PKI-STSP 
(Fig. 3 A and B) and no greater inhibition was observed at a higher dose of 25 nM in 
either tissue (data not shown). As PKI-STSP selectively inhibits PKC at the lower 
concentration of 5 nM and various protein kineses, including PKA, PKG, and CaMKII, 
at the higher concentrations of 25 nM (Tamaoki et al., 1986), our results indicate that 
PKC is likely involved in sustained activation of ADP-ribosyl cyclase. This was 
confirmed by using a more specific PKC inhibitor, calphostin C (100 nM), in both 
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tissues challenged by these two concentrations (Fig. 3). PKI-STSP or calphostin C alone 
had no essential effect on cyclase activity (n=3). Taken together, these results indicate 
that PKC may play a role in activating ADP-ribosyl cyclase by OT.  
 
3.3. Role of kinases in OT-induced activation of the ADP-ribosyl cyclase 
 
In isolated nerve endings of the neurohypophysis, it is easy to identify oxytocinergic 
nerve endings from those of vasopressin because of their larger size (Hlubek et al., 
2003; Sheikh et al., 1998; Troadec et al., 1998). This distinct morphology makes it 
possible to measure intracellular calcium mobilization upon OT stimulation over a 
period of 5 min. OT-induced changes in [Ca2+]i were measured in each single nerve 
ending with OGB-1 before, during, and after application of OT, to examine downstream 
Ca2+ signal transduction of elevated ADP-ribosyl cyclase activity. Application of the 
supramaximal concentration of 100 pM OT to the nerve endings for full activation 
resulted in two phases of [Ca2+]i increase in it’s time course: a rapid initial increase and 
a sustained elevation lasting for 5 min (Fig. 4A). OT elicited elevations of the maximum 
[Ca2+]i to 145 ± 21% (n=4) 20s after application. Two µM Xestospongin C, an IP3 
receptor antagonist, slowed down the initial increase with little or no effect on the 
sustained [Ca2+]i increases. Pretreatment with 10 µM 8-bromo-cADPR, an antagonistic 
cADPR analog, markedly inhibited OT-mediated sustained [Ca2+]i  increases with 
decreased initial increases, resembling the effect of vasotocin. In contrast, calphostin C 
had little effect on the initial phase followed by significant decreases at the sustained 
level, indicating that PKC is involved in the sustained [Ca2+]i elevation. Under Ca2+-free 
conditions, the OT-mediated increase of [Ca2+]i showed slight but not statistically 
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significant changes in both phases. The intensity modulation in initial and sustained 
[Ca2+]i elevation at 20 and 180 s after OT stimulation are summarized quantitatively in 
Fig. 4B and C, respectively. These results clearly showed that IP3 and cADPR inhibitors 
act differentially on the two phases of [Ca2+]i elevations. In most of experiments, nerve 
endings were tested for identifying as oxytocinergic endings by OT immunostaining 
after [Ca2+]i measurements (data not shown). 
 
3.4. Effects of OT on promoting OT release from isolated nerve-endings 
 
Finally, we examined OT-induced OT release from isolated nerve-endings during 5 min 
under various conditions. Following application of 100 pM OT, the release of OT was 
increased by 2.07-fold to the concentration of 1.39 ± 0.12 arbitrary unit  (n=4) for 5 
min from the control level with vasotocin (0.67 ± 0.05 arbitrary unit, n=4; Fig. 5). The 
effect of OT-mediated OT release was significantly inhibited by addition of calphostin C 
and 8-bromo-cADPR to the level induced by vasotocin. Two µM Xestospongin C had a 
significant inhibitory effect on OT release, while the Ca2+-free condition had a non 
significant inhibitory effect, consequently they changed to similar level. The sensitivity 
of antagonists on autoregulation of OT release (Fig. 5) resembles the inhibitory pattern 





The results of the present study indicated that OT-stimulated ADP-ribosyl cyclase 
activity and increases in [Ca2+]i were susceptible to PKC in both hypothalamus and/or 
posterior pituitary and OT-induced elevation in [Ca2+]i and subsequent OT release were 
both sensitive to PKC and dependent on cADPR. Therefore, we showed here that 
OT-induced OT release, autoregulation of the positive feedback, is a PKC- and 
cADPR-dependent process in the hypothalamus and/or pituitary. As we used 
10-12-week-old adult male mice, this PKC- and cADPR-dependent autoregulation of 
OT release is not related to female reproductive processes, but to social recognition or 
social behavior found in this mouse strain (Jin et al., 2007a; Liu et al., 2008). The 
positive feedback mechanism of OT release plays a critical and physiological role in 
causing uterus contraction during labor and triggering milk release from the breast 
tissue when infants are nursed (Moos et al., 1984; Neumann et al., 1994 and 1996). A 
recent series of studies showed that nasal infusion of OT increases trust (Kosfeld et al., 
2005), mind-reading (Domes et al., 2007), and generosity (Zak et al., 2007) in humans, 
indicating an important role of OT in human social behavior. Furthermore, OT reduces 
repetitive behavior in adults with autism and Asperger’s disorder (Hollander et al., 
2003). Taken together, positive feedback of PKC- and cADPR-dependent OT release in 
the hypothalamus and pituitary may be important for correct and efficient social 
conduct in relation to social stimulation, although further validation is necessary. 
The activation efficiency of OT on ADP-ribosyl cyclase activity differed 
markedly between the hypothalamus and pituitary (Fig. 1). The maximum peak 
obtained was 1,000-fold more sensitive in the pituitary, though basal activity was lower 
by 25%. The activation ratio was also higher in the pituitary than in the hypothalamus. 
For this, one reason may reside on cyclase species: the lower expression of CD38 in the 
 14 
pitutitary (Jin et al., 2007a) or contribution of other molecular species, as suggested in 
the embryonic brain (Ceni et al., 2006). The second possibility is utilization of different 
G proteins or accessory molecules. As shown in our results with GTP reproduced both 
stimulatory and inhibitory effects on cyclase, with the different mode in the 
hypothalamus and pituitary. Since higher concentrations of OT lost activation in the 
hypothalamus and pituitary tissues, as seen in myocardial cells (Higashida et al., 1999), 
stimulatory and inhibitory G proteins coupled to OT receptors may be involved at 
different OT concentrations. Third, close inspection of the dose-response curve of 
cADPR formation in the hypothalamus, one more highly sensitive component seems to 
be present in response to OT at around 100 nM (Fig. 2).  
We have demonstrated that the rise of [Ca2+]i in the isolated nerve endings after 
OT stimulation was dually controlled by IP3 and cADPR, resembling human 
myometrium cells (Barata et al., 2004). The initial part of the increase in [Ca2+]i seemed 
to be composed of IP3-mediated [Ca2+]i increases without Ca2+influx, because the IP3 
antagonist delayed the initial peak. In contrast, the cADPR was largely responsible for 
the sustained Ca2+ signal for up to 5 min because of blockade by the pretreatment of 
nerve endings with 8-bromo-cADPR, which was also mimicked by the PKC inhibitor. 
Thus, we postulated that the OT-induced Ca2+ elevation is due to release mediated by 
cADPR through ryanodine receptors in a PKC-dependent manner, followed by initial 
Ca2+ mobilization by activation of the IP3 receptors, which was not sensitive to PKC. A 
similar susceptibility pattern to inhibitors was obtained for OT-mediated OT release in 
the isolated nerve endings, indicating that OT release is dependent on the sustained 
phase of Ca2+ increases.  
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Involvement of CD38 in the cADPR-dependent signal cascade could be 
examined by using CD38 knockout mice as a tool. Since more than 90% of cyclase 
activity is lost in membrane fractions of the CD38 knockout mouse hypothalamus and 
pituitary, no or little increase in cyclase activity was confirmed in response to OT.  
Next, we measured [Ca2+]i in an isolated nerve-endings from CD38 knockout mice 
during 5 min under OT stimulation. In response to application of 100 pM OT, [Ca2+]i 
concentrations increased by 12 ± 6 % (n=4) in CD38 knockout mice and by 39 ± 12 % 
(n=4) in wild-type mice. These preliminary results suggest that OT receptor on 
stimulation can induce OT release by the initial Ca2+ increase, but CD38 and 
cADPR/dependent sustained Ca2+ increases can contribute facilitated OT release.  
In conclusion, the results confirm OT-mediated OT release in male mice, and 
this process is cADPR and Ca2+ dependent, with the mediation of PKC, The 
involvement of PKC in ADP ribosyl cyclase activity stimulation, [Ca2+]i increases and 
OT release, however, the whole intracellular mechanism of the downstream signaling 
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Fig. 1. OT increases ADP-ribosil cyclase activity in mouse hypothalamus and posterior 
pituitary. ADP-ribosyl cyclase activities were measured as the rate of cyclic GDP-ribose 
formation (pmol/min/mg protein) by homogenates isolated from mouse hypothalamus 
(A) and posterior pituitary (B). Data were presented as activities measured for 5 min 
under various concentrations of OT with (red line) or without 1µM oxytocin receptor 
antagonist vasotocin (blue line). The data shown are means ± SE (n=5). * p<0.05 from 
the presence of vasotocin. 
 
Fig. 2. cADPR content in mouse hypothalamus. Values were obtained during incubation 
for 5 min with various concentrations of OT. Data are presented as the means ± SE 
(n=4). * p<0.05, ** p<0.01. 
 
Fig. 3. Inhibition of OT-induced activation of the ADP-ribosyl cyclase. Data are 
presented as percentages of control cyclic GDP-ribose formation activity, as shown in 
Fig. 1. Activities were measured in the presence or absence of OT (4 concentrations), 
PKI-STSP (5 nM) or PKC-inhibitor calphostin C (100 nM) indicated in hypothalamus 
(A) and pituitary (B). Data are shown as means ± SE (n=4). * p<0.05, ** p<0.01from 
OT stimulation. 
 
Fig. 4. OT mediated changes in [Ca2+]i in single nerve endings isolated from the 
posterior pituitary. (A) Average time courses of changes in [Ca2+]i elicited with 100 pM 
OT with or without 1 µM oxytocin receptor antagonist vasotocin, 100 nM 
 23 
PKC-inhibitor calphostin C, 2 µM IP3-inhibitor Xestospongin C, 100 µM 
8-bromo-cADPR, and extracellular Ca2+. Average increases in [Ca2+]i measured at 20 s 
(B) and 180 s (C) after OT stimulation. Data are shown in change in fluorescence 
divided by resting fluorescence, i.e., ∆F/F0, as means ± SE (n=4-6). * p<0.05 in 
comparison with OT stimulation. 
 
Fig. 5. OT released from isolated nerve endings of posterior pituitary. OT 
concentrations are presented in OT release ratio (arbitrary unit) in an isolated nerve 
endings under 100 pM OT stimulation (5 min) with or without 1 µM oxytocin receptor 
antagonist vasotocin, 100 nM PKC-inhibitor calphostin C, 2 µM IP3-inhibitor 
Xestospongin C, 100 µM 8-bromo-cADPR, and extracellular Ca2+. Data are shown as 
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